Pfizer lifts annual sales forecast for COVID-19 vaccine By Reuters

0
17

© Reuters. FILE PHOTO: A man receives a second dose of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) at the hall three of the Belgrade Fair, in Belgrade, Serbia, April 13, 2021. REUTERS/Marko Djurica

(Reuters) – Pfizer Inc (NYSE:) on Tuesday raised its annual sales forecast for the COVID-19 vaccine it co-developed with Germany’s BioNTech SE (NASDAQ:), as a vaccination drive across the globe intensifies.

The U.S. drugmaker now expects sales of $26 billion from the vaccine in 2021, up from its prior forecast of about $15 billion. The goal assumes that 1.6 billion vaccine doses will be delivered in the year.

Cost and gross profit from the vaccine are split 50-50 between Pfizer and BioNTech.

Pfizer has said it expects to profit from the vaccine, while some drugmakers including Johnson & Johnson (NYSE:) have said their vaccine will be available on a not-for-profit basis until the end of the pandemic.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.